Cabaletta Bio Newsroom

Cabaletta Bio Analyst Ratings

BenzingaOct 10 21:29

UBS Initiates Cabaletta Bio(CABA.US) With Buy Rating, Announces Target Price $10

Futu NewsOct 10 18:31

Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $26

Futu NewsSep 26 20:31

HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target

BenzingaSep 17 19:32

H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25

Futu NewsSep 17 18:31

Evercore ISI Cuts Price Target on Cabaletta Bio to $15 From $25, Keeps Outperform Rating

MT NewswiresAug 26 19:27

Wells Fargo Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $20

Futu NewsAug 20 20:33

Buy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease Treatment

TipRanksAug 20 19:39

Cabaletta Bio Price Target Cut to $20.00/Share From $35.00 by Wells Fargo

Dow JonesAug 13 01:51

Cabaletta Bio Analyst Ratings

BenzingaAug 13 01:43

Evercore ISI Group Maintains Outperform on Cabaletta Bio, Lowers Price Target to $15

BenzingaAug 12 21:57

Cabaletta Bio: Overweight Rating Maintained Amidst ICANS Incident and Adjusted Price Target

TipRanksAug 12 18:44

HC Wainwright & Co. Maintains Buy on Cabaletta Bio, Lowers Price Target to $25

BenzingaAug 10 05:02

Cabaletta Bio Analyst Ratings

BenzingaAug 10 05:00

Cabaletta Bio: A Buy Recommendation Despite Safety Incident, With Anticipated Future Growth in Autoimmune CAR-T

TipRanksAug 9 03:57

William Blair Sticks to Its Buy Rating for Cabaletta Bio (CABA)

TipRanksAug 9 00:59

Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target

BenzingaJun 21 23:20

Cabaletta Bio Analyst Ratings

BenzingaJun 21 23:18

HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target

BenzingaJun 14 23:10

Cabaletta Bio Analyst Ratings

BenzingaJun 14 23:08